Dublin, Oct. 17, 2023 (GLOBE NEWSWIRE) -- The "DNA Encoded Library: Platforms and Services Market (2nd Edition), 2023-2035" report has been added to ResearchAndMarkets.com's offering.
The global DNA encoded library market is poised for substantial growth, with an estimated worth of USD 840 million in 2023 and a projected compound annual growth rate (CAGR) of 16% during the forecast period spanning 2023 to 2035.
DNA Encoded Libraries: A Catalyst for Drug Discovery
DNA encoded libraries (DELs) have emerged as a transformative platform for drug discovery, revolutionizing the synthesis and screening of millions of small molecules within a single study. DELs consist of small molecules tagged with DNA, serving as unique barcodes for molecule identification. Their adoption has gained momentum in recent years, significantly expediting drug discovery by reducing time and cost compared to traditional high-throughput screening methods.
Rising Demand for Innovative Therapies Drives Market Growth
The demand for innovative therapies to combat complex diseases such as oncological and neurological disorders has propelled the development of DNA encoded libraries. Pharmaceutical and biotechnology companies, academic institutions, and contract research organizations have increasingly embraced DEL technology, further driving market growth. With robust innovation and substantial financial support from investors, the DNA encoded library market is poised for remarkable expansion.
Key Market Insights:
- Lead Screening and Optimization: DELs, with their sophisticated combinatorial drug discovery capabilities, have enabled the synthesis and screening of vast collections of small molecule compounds. They facilitate the identification of pharmacological leads, including macrocycles, natural products, and small molecules, with some libraries containing up to 40 trillion unique molecules. DELs are instrumental in lead optimization against challenging targets, accelerating drug development.
- Competitive Landscape: The market features around 50 companies, both large and small, providing various services related to DNA encoded libraries for drug discovery, including hit identification, optimization, and lead generation. Notably, several major pharmaceutical companies, such as Amgen, GSK, Pfizer, Roche, Novartis, AstraZeneca, Bristol Myers Squibb, Sanofi, and Janssen, have adopted DEL technology for drug discovery.
- AI and Machine Learning Integration: The integration of artificial intelligence (AI) and machine learning has found a natural fit in DNA encoded chemical library platforms, enhancing data analytics capabilities. Companies like Insitro and Google Research have embraced this technology to expedite drug discovery.
- Strategic Alliances and Acquisitions: Stakeholders have formed strategic partnerships and made acquisitions to expand their capabilities. Over 175 partnerships have been inked in the DNA encoded library market since 2010. For example, X-Chem acquired Glamorous.AI to incorporate AI in DELs.
- Funding and Intellectual Property: The market has attracted significant investment, with close to USD 2.5 billion raised in recent years. Venture capital firms have been active supporters. Additionally, patent filings in the industry have grown at a rate of over 20% in the last decade, reflecting rising interest in DEL technology.
Market Analysis and Regional Dominance:
The global DNA encoded library market is estimated to reach USD 840 million in 2023. North America is expected to hold the largest market share, with more than 70% of the market captured by players based in North America and Europe by 2035. These companies will support pharmaceutical drug developers in their drug discovery initiatives through various business models.
Leading DNA Encoded Library Companies:
Key players in the DNA encoded library market include BOC Sciences, DyNAbind, Edelris, GenScript, HitGen, NovAliX, PROVendis, SpiroChem, Vipergen, WuXi AppTec, and X-Chem.
Recent Developments:
Recent initiatives in the DNA encoded library market include collaborations between Philogen and Google, X-Chem and Kymera Therapeutics, and X-Chem and Sironax, focusing on the utilization of machine learning, DEL-based screening services, and drug discovery pipeline support.
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. MARKET LANDSCAPE
5. BUSINESS MODEL ANALYSIS
6. COMPANY COMPETITIVENESS ANALYSIS
7. COMPANY PROFILES
8. PARTNERSHIPS AND COLLABORATIONS
9. FUNDING AND INVESTMENT ANALYSIS
10. PATENT ANALYSIS
11. BIG PHARMA INITIATIVES
12. CASE STUDY: COMPANIES / ORGANIZATIONS SUPPORTING THE DEVELOPMENT OF DNA ENCODED LIBRARIES
13. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14. CONCLUDING REMARKS
15. EXECUTIVE INSIGHTS
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Companies Mentioned
- 1859, Inc.
- 6 Dimensions Capital
- AbbVie
- Abilita Bio
- Actelion Pharmaceuticals
- Aduro Biotech
- Agent Capital
- Air Street Capital
- Alex's Lemonade Stand Foundation
- Alexandria Venture Investments
- Alexion
- Aligos Therapeutics
- ALK
- Alkermes
- Almac Discovery
- Almirall
- AlphaMa
- Altitude Life Science Ventures
- Amadeus Capital Partners
- Amgen
- Anagenex
- Anavo Therapeutics
- Andreessen Horowitz
- Animol Discovery
- Anterra Capital
- Arbutus Biopharma
- ARCH Venture Partners
- Arclight
- Arvinas
- ASINEX
- Astellas Pharma
- Astellas Venture Management
- AstraZeneca
- Asymmetry Capital Management
- Atlas Venture
- AviSyn Pharma (acquired by X-Chem)
- Azenta Life Sciences
- Bain Capital Life Sciences
- BASF
- Bayer
- Baylor College of Medicine
- BGF
- BigRio
- Bill & Melinda Gates Foundation
- BioAge Labs
- BioDuro-Sundia
- Biogen
- BIONET
- BOC Sciences
- Boehringer Ingelheim
- Borealis Ventures
- Boxer Capital
- Bpifrance
- Bridge Biotherapeutics
- Bristol Myers Squibb
- BVF Partners
- C4X Discovery
- Cambridge Enterprise
- Cambridge Molecular
- Canada Pension Plan Investment Board
- Cancer Research Technology
- Cancer Research UK
- Carterra
- Casdin Capital
- Casma Therapeutics
- Catalio Capital Management
- CDH Investments
- Cedilla Therapeutics
- Central European Institute of Technology
- Charles River
- Charles River Ventures
- ChemDiv
- ChemRoutes
- Chemspace
- Citadel Discovery
- Cocrystal Pharma
- Columbia University
- ComInnex (acquired by X-Chem)
- Confo Therapeutics
- Crelux
- Cyclofluidic
- D. E. Shaw
- Daewoong Pharmaceutical
- Daiichi Sankyo
- DCVC Bio
- Deep Track Capital
- Deluge Biotechnologies
- DICE Therapeutics
- Domainex
- Dorian Therapeutics
- Dresden University of Technology (TUD)
- Driehaus Capital Management
- Duke University
- DyNAbind
- EcoR1 Capital
- Edelris
- Eli Lilly
- Enamine
- Encodia
- Endevica Bio
- Enko
- EQRx
- ETH Zurich
- European Regional Development Fund (ERDF)
- Eventide Asset Management
- Evotec
- Exo Therapeutics
- Finistere Ventures
- Fisher Scientific
- Foresite Capital
- Forma Therapeutics
- Franzini Research
- Galapagos
- Genentech
- GenScript
- GHO Capital
- Gilead Sciences
- Glamorous AI (acquired by X-Chem)
- GlaxoSmithKline (GSK)
- Global Blood Therapeutics
- Google Ventures
- Harvard College
- Haystack Sciences (acquired by insitro)
- Heptares Therapeutics
- High-Tech Grunderfonds (HTGF)
- HitGen
- Hope City Church
- HotSpot Therapeutics
- Howard Hughes Medical Institute
- Innovate UK
- Inscripta
- insitro
- IntelliSyn (acquired by X-Chem)
- InterX (acquired by NeoTX)
- Janssen
- Janus Henderson Investors
- Johnson & Johnson
- Kaken Pharmaceutical
- Khosla Ventures
- Kymera Therapeutics
- Leadyond Capital
- LEO Pharma
- LG Chem
- LGC Biosearch Technologies
- Life Chemicals
- Lipigon
- Liverpool ChiroChem
- Logos Capital
- LoQus23 Therapeutics
- Lux Capital
- M Ventures
- Macroceutics (acquired by HotSpot Therapeutics)
- Maruho
- Max Planck Institute of Molecular Physiology (MPI)
- Mcule
- MD Anderson Cancer Center
- MedChemExpress (MCE)
- Menlo Ventures
- Merck
- Mitsubishi Tanabe Pharma
- MolPort
- Morningside Ventures
- Morphic Therapeutic
- Namiki Shoji
- Navitor Pharmaceuticals
- Neotribe Ventures
- NetVation DL Medicine
- New Leaf Venture Partners
- Newpath Partners
- Nextech Invest
- Nitrase Therapeutics
- Northpond Ventures
- Northwestern University
- Novalis LifeSciences
- NovAliX
- Novartis
- Novartis Venture Fund
- Nuevolution (acquired by Amgen)
- Nurix Therapeutics
- O2h Ventures
- Obvious Ventures
- OMass Therapeutics
- Oncodesign
- Ono Pharmaceutical
- Orbit Discovery
- Orexia
- Osage University Partners
- Otsuka Pharmaceutical
- Oxford Sciences Innovation
- Oxford University
- PACS1 Syndrome Research Foundation
- Pappas Capital
- Parkwalk Advisors
- Perceptive Advisors
- Perivoli Innovations
- Pfizer
- PharmaBlock Sciences
- Pharmacelera
- Pharmaceutical Product Development (PPD)
- Pharmaron
- PharmStars
- Philochem
- Philogen
- PhoreMost
- PhyNexus (acquired by Biotage)
- Pioneering Medicines
- Pivotal bioVenture Partners
- Plexium
- Praecis Pharmaceuticals (acquired by GSK )
- Princeton University
- Proteros Biostructures
- PROvendis
- PsyBrain
- Pulsar Bio
- RA Capital Management
- Receptor.AI
- Recludix Pharma
- Redmile Group
- Relay Therapeutics
- Roche
- Roivant Sciences
- RT Ventures
- S.R. One
- Sahsen Ventures
- Salipro Biotech
- Samsara BioCapital
- Sands Capital
- SanegeneBio
- Sanofi
- Sanofi Ventures
- SciLifeLab
- Scilligence
- Serengen
- Servier
- Signel IX
- Simcere Pharmaceutical
- Sironax
- Sofinnova Partners
- SoftBank Vision Fund
- Soleus Capital
- SpiroChem
- Sun Pharma Advanced Research Company (SPARC)
- Surveyor Capital (a Citadel company)
- Symeres
- SyntheX
- Taiho Pharmaceutical
- Takeda
- Tasly Pharmaceuticals
- Tavistock Group
- TCG Crossover (TCG X)
- Technical University of Dortmund
- Technology Founder Fund Saxony (TGFS )
- Temasek
- The California Institute for Biomedical Research (Calibr)
- The Column Group (TCG)
- The Scripps Research Institute
- Theseus Pharmaceuticals
- Third Rock Ventures
- Trend Investment Group
- Trilo Therapeutics
- TUDAG
- Two Sigma Ventures
- UNC Drug Discovery Initiative
- University of Edinburgh
- University of Manchester
- University of Pennsylvania
- UPPthera
- Valo Health
- Veritas In Silico
- Vernalis Research (acquired by HitGen)
- Vertex Pharmaceuticals
- Vipergen
- Viva Biotech
- Wake Forest University
- Warp Drive Bio
- Wellington Management Company
- WuXi AppTec
- X-Chem
- XtalPi
- Zai Lab
- ZebiAI (acquired by Relay Therapeutics)
For more information about this report visit https://www.researchandmarkets.com/r/xcup3a
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
